Exact Sciences' shares rise 6.8% following CMS reimbursement decision, Modernizing Medicine closes gMed acquisition & more – 4 GI/endoscopy company key notes

Here are four recent news updates on gastroenterology and endoscopy companies.

Zacks Investment Research noted EndoChoice has been assigned a consensus broker rating score of 1.00 — strong buy — from the four brokers that provide coverage for the company.

Following CMS' decision to maintain Medicare reimbursement for Cologuard, Exact Sciences' shares rose 6.8 percent, according to a Journal Sentinel report.

Modernizing Medicine completed the previously announced acquisition of gMed.

The American Gastroenterological Association, Crohn's & Colitis Foundation of America and Janssen Biotech selected Theresa Alenghat, VMD, PhD as the inaugural winner of the 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease Epigenetics Research.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

More articles on gastroenterology:
Kentucky to receive $2.6M for improving CRC screenings, outcomes: 4 key notes
To stay or go? When GI physicians consider changing practice settings
CMS votes to uphold Medicare reimbursement for Cologuard

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months